title: Association of anti-modified citrullinated vimentin with subclinical atherosclerosis in early rheumatoid arthritis compared with anti-cyclic citrullinated peptide.
abstract: OBJECTIVE
  To investigate anti-modified citrullinated vimentin (anti-MCV) in early rheumatoid arthritis (RA), including correlation with disease activity and cardiovascular risk factors, compared with anti-cyclic citrullinated peptides (anti-CCP3).
  
  
  METHODS
  Anti-MCV and anti-CCP3 concentrations were measured in 100 patients with early RA and 100 healthy controls at baseline to determine sensitivity and specificity. Patients received methotrexate (MTX) 0.2 mg/kg/week plus prednisone 10 mg/day. Anti-MCV, anti-CCP3, rheumatoid factor (RF), Disease Activity Score for 28 joints (DAS-28), lipid profile, erythrocyte sedimentation rate (ESR), high-sensitivity C-reactive protein assay (hsCRP), homeostasis model assessment for insulin resistance (HOMA-IR) index, tumor necrosis factor-α (TNF-α), interleukin 6 (IL-6), and carotid intima-media thickness (cIMT) were measured before and after 12 months of treatment.
  
  
  RESULTS
  The sensitivity and specificity for anti-MCV antibody were 75% and 90%, respectively, and for anti-CCP3 antibody 71% and 96%. Serum anti-MCV and serum anti-CCP3 levels at baseline were positively correlated with hsCRP, IL-6, HOMA-IR index, serum RF levels (p < 0.001), and cIMT (p < 0.05). Serum anti-MCV was positively correlated with serum anti-CCP3 levels. There were significant positive correlations between the percentage of changes of anti-MCV levels versus changes in DAS-28, ESR, hsCRP, atherogenic ratios (TC/HDL-C and LDL-C/HDL-C), apolipoprotein A-I, IL-6, TNF-α, HOMA-IR index, and cIMT. These correlations were not found between changes in anti-CCP3 levels compared to clinical, laboratory, and radiological variables.
  
  
  CONCLUSIONS
  Anti-MCV was as sensitive as anti-CCP3 in diagnosing early RA. Anti-MCV testing appears to be useful for monitoring associated subclinical atherosclerosis in early RA.
authors.affiliation: Department of Rheumatology and Rehabilitation, Tanta University Faculty of Medicine, Elgesh Street, Tanta, Gharbeia, Egypt. ml_barbary@yahoo.com
authors.forename: Amal M
authors.initials: AM
authors.lastname: El-Barbary
authors.forename: Elham M
authors.initials: EM
authors.lastname: Kassem
authors.forename: Mervat A S
authors.initials: MA
authors.lastname: El-Sergany
authors.forename: Salwa A-M
authors.initials: SA
authors.lastname: Essa
authors.forename: Mohamed A
authors.initials: MA
authors.lastname: Eltomey
mesh_terms: D000328:Adult; D000368:Aged; D000888:Antibodies, Anti-Idiotypic / Q000097:blood*; D016632:Apolipoprotein A-I / Q000097:blood; D001055:Apolipoproteins B / Q000097:blood; D001172:Arthritis, Rheumatoid / Q000276:immunology*; D050197:Atherosclerosis / Q000276:immunology*; D001323:Autoantibodies / Q000097:blood*; D017536:Carotid Artery, Common / Q000000981:diagnostic imaging; D002956:Citrulline / Q000276:immunology*; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009391:Nephelometry and Turbidimetry; D010456:Peptides, Cyclic / Q000276:immunology; D012307:Risk Factors; D012680:Sensitivity and Specificity; D012720:Severity of Illness Index; D014463:Ultrasonography; D014746:Vimentin / Q000276:immunology*
chemical_list: D000888:Antibodies, Anti-Idiotypic; D016632:Apolipoprotein A-I; D001055:Apolipoproteins B; D001323:Autoantibodies; D010456:Peptides, Cyclic; D014746:Vimentin; C487763:cyclic citrullinated peptide; D002956:Citrulline